OTC: STEK
Stemtech CorpCIK 0001511820 · SIC 5122 · Drugs & Sundries
Micro
Revenue $3M
Assets $3M
as of Sep 13, 2026
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (FUL 10-Q) is open in full — no account needed.
10-Q
Filed Aug 14, 2026
· Period ending Jun 30, 2026
Summary not yet generated.
10-Q
Filed Jun 22, 2026
· Period ending Mar 31, 2026
Summary not yet generated.
Partner
Trade STEK commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
10-K
Filed May 29, 2026
· Period ending Dec 31, 2025
Summary not yet generated.
10-Q
Filed Nov 19, 2025
· Period ending Sep 30, 2025
Summary not yet generated.
10-Q
Filed Aug 19, 2025
· Period ending Jun 30, 2025
Summary not yet generated.
10-Q
Filed Jul 17, 2025
· Period ending Mar 31, 2025
Summary not yet generated.
10-K
Filed Jun 30, 2025
· Period ending Dec 31, 2024
Summary not yet generated.
8-K
Filed Apr 14, 2025
· Period ending Apr 11, 2025
Summary not yet generated.
8-K
Filed Jan 3, 2025
· Period ending Dec 30, 2024
Summary not yet generated.
8-K
Filed Dec 6, 2024
· Period ending Dec 2, 2024
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 14, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| NET SALES | 629,312 | 697,925 | 1,092,269 | 1,565,971 |
| COST OF GOODS SOLD: | – | – | – | – |
| Cost of goods sold | 158,152 | 126,820 | 257,398 | 256,907 |
| Freight-in | 5,487 | 19,089 | 14,891 | 36,784 |
| TOTAL COST OF GOODS SOLD | 163,639 | 145,909 | 272,289 | 293,691 |
| GROSS PROFIT | 465,673 | 552,016 | 819,980 | 1,272,280 |
| OPERATING EXPENSES: | – | – | – | – |
| Commissions | 48,754 | 121,210 | 105,192 | 306,768 |
| Selling and marketing | 2,767 | 33,807 | 6,813 | 46,051 |
| General and administrative | 539,719 | 697,987 | 1,835,971 | 2,425,354 |
| Research and development | – | – | – | – |
| TOTAL OPERATING EXPENSES | 591,240 | 853,004 | 1,947,976 | 2,778,173 |
| OPERATING LOSS | (125,567) | (300,988) | (1,127,996) | (1,505,893) |
| OTHER INCOME (EXPENSE): | – | – | – | – |
| Change in fair value of derivative liability | – | – | – | – |
| Interest expense | (112,734) | (79,727) | (210,393) | (325,095) |
| Other income and expenses, net | – | 84,435 | – | 75,982 |
| Gain on settlement of derivative liabilities | – | – | – | – |
| Gain (loss) on extinguishment of debt | (54,057) | – | (115,029) | – |
| Loss on disposal of assets | – | – | – | – |
| TOTAL OTHER INCOME (EXPENSE) | (166,791) | 4,708 | (325,422) | (249,113) |
| INCOME (LOSS) BEFORE INCOME TAXES | (292,358) | (296,280) | (1,453,418) | (1,755,006) |
| PROVISION FOR INCOME TAXES | – | – | – | – |
| NET LOSS | (292,358) | (296,280) | (1,453,418) | (1,755,006) |
| NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTERESTS | – | (3,135) | – | (3,135) |
| NET LOSS AVAILABLE TO COMMON STOCKHOLDERS | (292,358) | (293,145) | (1,453,418) | (1,751,871) |
| Net loss per common share | – | – | – | – |
| Basic | (0.00) | (0.00) | (0.00) | (0.01) |
| Diluted | (0.00) | (0.00) | (0.00) | (0.01) |
| Shares used to compute loss per share | – | – | – | – |
| Basic | 2,077,445,090 | 142,443,444 | 1,448,285,968 | 140,183,928 |
| Diluted | 2,077,445,090 | 142,443,444 | 1,448,285,968 | 140,183,928 |
| Comprehensive loss | – | – | – | – |
| Net loss | (292,358) | (293,145) | (1,453,418) | (1,751,871) |
| Change in foreign currency translation adjustments | (53,305) | 682,291 | 311,938 | (213,465) |
| Comprehensive loss available to common stockholders | (345,663) | 389,146 | (1,141,480) | (1,965,336) |
Consolidated Balance Sheets (Unaudited)
| Description | June 30, 2026 | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| CURRENT ASSETS: | ||
| Cash | 246,772 | 238,245 |
| Accounts receivable, net | – | – |
| Inventory, net | 311,277 | 217,338 |
| Prepaid expenses and other current assets | 13,184 | 1,479 |
| TOTAL CURRENT ASSETS | 571,233 | 457,062 |
| Property and equipment, net | ||
| Intangible assets, net | 2,124,917 | 2,208,663 |
| Other long term assets | – | – |
| Long term deposits | – | 16,480 |
| Operating lease right-of-use assets net | – | – |
| Goodwill | 467,409 | 467,409 |
| Intercompany | – | – |
| TOTAL ASSETS | 3,163,559 | 3,149,614 |
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||
| CURRENT LIABILITIES: | ||
| Accounts payable and accrued expenses | 5,920,378 | 5,410,261 |
| Notes payable | 2,564,020 | 2,336,554 |
| Convertible debentures, net of discount | 1,832,414 | 1,825,645 |
| Operating lease liabilities current | – | – |
| Deferred revenues | 3,234 | 171,485 |
| Factoring liability | 792,918 | 843,068 |
| Derivative liability | – | – |
| TOTAL CURRENT LIABILITIES | 11,112,964 | 10,587,013 |
| Notes payable Long term | – | – |
| Operating lease liabilities noncurrent | – | – |
| Other long term liabilities | – | – |
| TOTAL LIABILITIES | 11,112,964 | 10,587,013 |
| COMMITMENTS AND CONTINGENCIES (Note 12) | 267,000 | 267,000 |
| STOCKHOLDERS' EQUITY | ||
| Common stock $0.001 par value; 5,000,000,000 shares authorized; 2,738,521,585 and 425,980,711 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 2,738,522 | 425,981 |
| Additional paid in capital | 25,949,830 | 27,632,897 |
| Accumulated other comprehensive loss | 172,181 | (139,757) |
| Accumulated deficit | (36,331,175) | (34,877,757) |
| Stemtech Corporation shareholders’ deficit | (7,470,642) | (6,958,636) |
| Non-controlling interest in subsidiaries | (745,763) | (745,763) |
| Net loss | – | – |
| TOTAL STOCKHOLDERS EQUITY | (8,216,405) | (7,704,399) |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | 3,163,559 | 3,149,614 |
Consolidated Statements of Cash Flows (Unaudited)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Net loss | (1,453,418) | (1,755,006) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 83,746 | 83,753 |
| Amortization of right of use asset | – | – |
| Operating lease liabilities | – | – |
| Stock compensation expense | 217,723 | 217,722 |
| Non-cash interest expense from issuance on debt (derivative) | – | – |
| Amortization of debt discount | 6,769 | (43,594) |
| Change in fair value of derivative liabilities | – | – |
| Gain (loss) on settlement of derivative liabilities | – | – |
| Cancellation of shares returned by shareholders | – | – |
| Stock issued for services | 296,723 | 211,809 |
| (Gain) loss on extinguishment of debt | 115,029 | – |
| Changes in operating assets and liabilities, net of effect of acquisitions: | ||
| Accounts receivable | – | (77,696) |
| Inventory | (93,939) | (77,452) |
| Prepaid expenses and other current assets | (11,705) | (1,816) |
| Accounts payable and accrued expenses | 510,116 | 709,487 |
| Long term deposits | 16,480 | 452 |
| Operating lease liabilities | – | – |
| Deferred revenues | (168,251) | 96,786 |
| Net cash used in operating activities | (480,727) | (635,555) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchase of property and equipment | – | – |
| Net cash used in investing activities | – | – |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Proceeds from notes payable | 227,466 | 478,229 |
| Net proceeds from factoring arrangement | (50,150) | 183,307 |
| Repayment of note payable | – | (109,402) |
| Stock issued for cash | – | – |
| Proceeds from note payable related parties | – | – |
| Net cash provided (used) by financing activities | 177,316 | 552,134 |
| Effects of currency translation on cash | 311,938 | 100,573 |
| Net increase (decrease) in cash | 8,527 | 17,152 |
| Cash, beginning of period | 238,245 | 255,298 |
| Cash, end of period | 246,772 | 272,450 |
| Supplemental disclosure cash flow information: | ||
| Cash paid for interest | – | – |
| Cash paid for income taxes | – | – |
Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗